Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Conditions: Diffuse Large B Cell Lymphoma Interventions: Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide Sponsors: Yan Zhang, MD; Peking University Third Hospital; Peking University First Hospital; Chinese PLA General Hospital Recruiting

https://clinicaltrials.gov/study/NCT06176729

Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials